Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies.

Acta endocrinologica - 1 Jul 1993

Vialettes B, Guillerand M A, Viens P, Stoppa A M, Baume D, Sauvan R, Pasquier J, San Marco M, Olive D, Maraninchi D

Abstract excerpt

Immunotherapy using recombinant interleukin 2 (rIL-2) has been shown to induce thyroid dysfunction in some cancer patients. The purpose of the present study was to evaluate the incidence and risk factors of this adverse autoimmune response. Triiodothyronine, thyroxine and thyrotropin levels were measured serially in 146 consecutive patients treated with rIL-2 for refractory solid tumor (77 patients) or malign...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Incidence

Share to Interleukin-2

Share to Neoplasms

Share to Phenotype

Share to Recombinant Proteins

Share to Risk Factors

Source

Identifiers

PMID: 8351956
DOI: 10.1530/acta.0.1290031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies.PMID 8351956Read ↗

Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.Semantic proximity Read ↗

Cases of interferon-alpha and interferon-beta-induced thyroiditis.Semantic proximity Read ↗

Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.Semantic proximity Read ↗

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.Semantic proximity Read ↗

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer.Semantic proximity Read ↗

Generation and characterization of lymphokine-activated killer cells from non-Hodgkin's lymphoma patients.Semantic proximity Read ↗

Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose.Semantic proximity Read ↗

Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.Semantic proximity Read ↗

A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects.Semantic proximity Read ↗

Analysis of liver lymphoid cell subsets pre- and post-in vivo administration of human recombinant interleukin 2 in a C57BL/6 murine system.Semantic proximity Read ↗

Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.Semantic proximity Read ↗

Mitogenic effect of interleukin-2 on unstimulated human T cells: an editorial review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.